Stada Arz in-licenses teriparatide, expanding its biosimilars portfolio

German generic and branded drugmaker Stada Arzneimittel (SAZ: GR) has in-licensed osteoporosis drug teriparatide, expanding its biosimilars portfolio.

The teriparatide biosimilar is being developed by Richter-Helm BioTec GmbH, a Hamburg-based developer of biosimilar drugs, and is to be launched under the Stada label throughout Europe following the expiration of the patent of the original product, Forsteo (teriparatide) from US pharma major Eli Lilly (NYSE: LLY).

“With this additional in-licensing, we are consequently following our biosimilar strategy according to which we rely on cooperations with highly specialized partners to expand our portfolio at favorable conditions with high-quality products,” explains chairman of the executive board of Stada, Hartmut Retzlaff.